Zdrowie i gospodarka · 24.12.2002
Trimethobenzamide Hydrochloride Injection and Capsules; Drug Efficacy Study Implementation; Final Evaluation
The Food and Drug Administration (FDA) announces the resolution of issues concerning trimethobenzamide hydrochloride injection and capsules. This notice announces the approval of a supplemental new drug application (NDA) for Tigan (trimethobenzamide hydrochloride) Capsules, 300 milligrams (mg), and states that continued marketing of unapproved trimethobenzamide hydrochloride injection and capsule products is unlawful and is subject to FDA regulatory action.